Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB)’s share price gapped down before the market opened on Monday . The stock had previously closed at $0.80, but opened at $0.90. Matinas BioPharma shares last traded at $0.83, with a volume of 24389 shares.
Separately, Maxim Group lowered their price objective on shares of Matinas BioPharma from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Monday, August 13th.
Matinas BioPharma (NYSEAMERICAN:MTNB) last released its earnings results on Friday, August 10th. The company reported ($0.04) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.04). The firm had revenue of $0.09 million during the quarter. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%.
Matinas BioPharma Company Profile (NYSEAMERICAN:MTNB)
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Further Reading: Day Trading
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.